FibroGen’s Roxadustat On The Rocks After Phase III Myelodysplastic Syndrome Failure

MATTERHORN’s failure did not surprise analysts, but it’s likely the end of the road for roxadustat in the US market. The focus instead has shifted to FibroGen’s IPF asset pamrevlumab.